Alnylam Pharmaceuticals
ALNY · NASDAQ
Bulios Fair Price
$132.51
48.2% downside
Trenutna cena
$255.96
Po podatkih Bulios Fair Price je delnica ALNY trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Alnylam Pharmaceuticals, Inc. is an American biotechnology company headquartered in Cambridge, Massachusetts. It focuses on the development of RNA-based therapeutics for the treatment of genetic diseases. The company specializes in RNA interference (RNAi) technology, which allows for the suppression of specific genes expression to treat genetic diseases at the gene level. Their research and development efforts target the treatment of various genetic diseases, including liver, kidney, muscle, and nervous system disorders. Alnylam Pharmaceuticals is known for its innovative approach to RNAi research and development of therapeutic agents for the treatment of rare diseases. The company collaborates with academic institutions, biotechnology firms, and pharmaceutical companies worldwide. Shares of Alnylam Pharmaceuticals, Inc. are publicly traded on the NASDAQ stock exchange.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Yvonne L. Greenstreet
Employees
2,500
Headquarters
Cambridge
Prihajajoči dogodki
Earnings
Upcoming earnings report